Top Zopiclone Brands for Quality Sleep Solutions

Zopiclone is a medication commonly prescribed to help with insomnia, aiding those who struggle with getting a good night's sleep. With various brands offering formulations of zopiclone, it becomes essential to choose the right one for effective and safe results. Some of the leading names in the market are recognized for their consistent quality and reliability, making them popular choices among healthcare providers and patients alike. To explore the details and advantages of these top brands, please see the information provided below.

Illustration of zopiclone

Best brands of zopiclone in 2025

Sandoz

Sandoz is a notable producer of zopiclone, a nonbenzodiazepine hypnotic used to treat insomnia, with their product available in 5mg and 7.5mg tablets, though availability may vary by region; Sandoz Zopiclone, while not currently manufactured for sale in Canada, remains a brand recognized in various global markets, demonstrating their established presence in the pharmaceutical industry, with zopiclone working by enhancing the effects of GABA in the central nervous system, similar to benzodiazepines; Sandoz's commitment to quality production and wide distribution reflects its role in providing access to this medication.

Teva

Teva is a notable manufacturer of zopiclone, a nonbenzodiazepine hypnotic used to treat insomnia, with a market share that reached 30-40% in value and 40-50% in volume in 2014, while also offering it in various dosages such as 3.75mg, 5mg, and 7.5mg tablets. Teva's zopiclone products are available in multiple countries, including Belgium and France, demonstrating a wide international presence. The drug works by enhancing the effects of GABA in the central nervous system to induce sleep, and while generally considered safe, zopiclone should be used short-term and under medical supervision due to potential side effects such as drowsiness, bitter taste, and possible interactions. For more information about Teva's Zopiclone.

Mylan

Mylan is a notable producer of zopiclone, a nonbenzodiazepine hypnotic used for short-term insomnia treatment, with a market share in Sweden reaching 60-70% in 2015 when combined with Meda, although Mylan's individual sales were very small at 13,400 units compared to Meda's 60 million units. Zopiclone is available in 5 mg and 7.5 mg doses and works by enhancing the effects of GABA in the central nervous system, generally recommended for short-term use of 2-4 weeks. Mylan's Zopiclone tablets are available in various countries, including Canada, where they are used to help induce sleep with effects felt within one hour, and are a prescription-only medication.

Accord Healthcare

Accord Healthcare is a global pharmaceutical company that develops, manufactures, and distributes generic medicines, including zopiclone, in over 85 countries, striving to improve patient access to essential care. While they do not have the largest market share for zopiclone, they are a significant supplier, offering both 3.75mg and 7.5mg tablets. Their product information, including the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL), is regularly updated, with recent updates made on August 15, 2024, for the 7.5mg tablets and April 8, 2024, for both 3.75mg and 7.5mg tablets. Accord is committed to innovation, aiming to improve existing medicines to better meet patient needs, and their packaging is designed to minimize errors in dispensing. They are also known for their broad portfolio that spans across critical therapeutic fields, such as oncology, cardiology, neurology, psychiatry, diabetes, pain management, and gastroenterology.

Lupin

Lupin is a key manufacturer of zopiclone, a nonbenzodiazepine hypnotic, with a presence in the global market since 2014, offering it as a generic option after brand name patents expired. With a bioavailability of around 80% and a half-life of approximately 5 hours, Lupin boasts a market coverage of over 76% in the Indian pharmaceutical market as of 2020. The company's product, Eszopiclone Tablets, CIV, is available in the US market. For more information, you can visit the Lupin Pharmaceuticals website.

Ranbaxy

While Ranbaxy is not the primary or largest manufacturer of zopiclone, it has produced and marketed the drug under the brand name "Ran-Zopiclone" since at least 2007, offering 5mg and 7.5mg tablets, and has been referenced in studies regarding zopiclone's solubility and effects. Although zopiclone was initially developed in 1986 by Rhône-Poulenc S.A. (now part of Sanofi), Ranbaxy has been a notable supplier of the medication, contributing to the availability of zopiclone as a non-benzodiazepine hypnotic agent for the treatment of insomnia, despite the fact that it can be misused and has some addictive properties. The cost for Ran-Zopiclone was 0.2231 per unit in some areas. For more information about the product, you can visit this website.

Sanofi

Sanofi, a leading pharmaceutical company, produces zopiclone, a non-benzodiazepine hypnotic, with their brand Imovane being a well-known option for short-term insomnia treatment, typically prescribed at 7.5mg doses for adults, while a 3.75mg dose is recommended for elderly patients and those with liver or kidney issues. Sanofi's zopiclone product is designed to reduce the time to sleep onset and nocturnal awakenings, improving overall sleep quality, with the treatment duration not exceeding four weeks to minimize dependency risk. While the global zopiclone API market is projected to reach a value in the billions by 2031, Sanofi continues to be a key player in the production and distribution of this medication, with their product Imovane initially approved in 2009 and revised in 2024.

Actavis

Actavis, a well-known pharmaceutical company, produces zopiclone, a medication used for short-term treatment of insomnia, and is marketed under the name Zopiclone Actavis. It is available in 3.75 mg and 7.5 mg tablets, with the 7.5 mg tablets being white to off-white and oval-shaped. The typical treatment period is 7-14 days, and the half-life of zopiclone after a single dose is approximately 5.26 hours. More information on Zopiclone Actavis can be found at the Medsafe website.

Aurobindo Pharma

Aurobindo Pharma is a notable manufacturer of zopiclone, a medication used to treat insomnia, with a strong presence in the European market, evidenced by its product availability across multiple countries and inclusion in various national formularies. While specific global market share data for Aurobindo's zopiclone production is not available, they are identified as a competitor in several markets and have been involved in acquisitions and divestments related to their pharmaceutical operations. The company offers zopiclone in different dosages, such as 3.75mg and 7.5mg, highlighting its focus on providing diverse options for patients. Their zopiclone product is available under the name "Zopiclon Aurobindo," often as a film-coated tablet. You can find more information about their specific zopiclone product, including its summary of product characteristics.

Sun Pharma

Sun Pharma is a key producer of zopiclone, a nonbenzodiazepine hypnotic, offering it in 5 mg and 7.5 mg tablet forms, with their RAN trademark recognized in the pharmaceutical industry. While they don't have a monopoly, they are among the leading manufacturers of this medication, as evidenced by their consistent presence in the market alongside other major players like Teva and Lupin. Zopiclone is primarily used for short-term treatment of insomnia, acting on the GABAa receptors in the brain to induce sleep. It's important to note that this medication is recommended for short term use only, generally for no more than 7 to 10 days, due to potential risks of dependence. For product information please check the official Sun Pharma website.